Clarity Pharmaceuticals Ltd CU6.AX Stock
Clarity Pharmaceuticals Ltd Price Chart
Clarity Pharmaceuticals Ltd CU6.AX Financial and Trading Overview
| Clarity Pharmaceuticals Ltd stock price | 2.64 AUD |
| Previous Close | 0.79 AUD |
| Open | 0.8 AUD |
| Bid | 0.74 AUD x N/A |
| Ask | 0.79 AUD x N/A |
| Day's Range | 0.75 - 0.8 AUD |
| 52 Week Range | 0.36 - 1.05 AUD |
| Volume | 63.48K AUD |
| Avg. Volume | 129.53K AUD |
| Market Cap | 205.7M AUD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.12 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.7 AUD |
CU6.AX Valuation Measures
| Enterprise Value | 137.03M AUD |
| Trailing P/E | N/A |
| Forward P/E | -8.777778 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 21.91959 |
| Price/Book (mrq) | 2.5079365 |
| Enterprise Value/Revenue | 14.603 |
| Enterprise Value/EBITDA | -6.271 |
Trading Information
Clarity Pharmaceuticals Ltd Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 80.45% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.05 AUD |
| 52 Week Low | 0.36 AUD |
| 50-Day Moving Average | 0.74 AUD |
| 200-Day Moving Average | 0.8 AUD |
CU6.AX Share Statistics
| Avg. Volume (3 month) | 129.53K AUD |
| Avg. Daily Volume (10-Days) | 188.65K AUD |
| Shares Outstanding | 260.38M |
| Float | 155.7M |
| Short Ratio | N/A |
| % Held by Insiders | 60.35% |
| % Held by Institutions | 10.51% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | -226.81% |
| Operating Margin (ttm) | -233.71% |
| Gross Margin | 100.00% |
| EBITDA Margin | -232.85% |
Management Effectiveness
| Return on Assets (ttm) | -14.17% |
| Return on Equity (ttm) | -23.27% |
Income Statement
| Revenue (ttm) | 9.38M AUD |
| Revenue Per Share (ttm) | 0.04 AUD |
| Quarterly Revenue Growth (yoy) | 104.20% |
| Gross Profit (ttm) | 6.46M AUD |
| EBITDA | -21851636 AUD |
| Net Income Avi to Common (ttm) | -21284840 AUD |
| Diluted EPS (ttm) | -0.08 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 75.89M AUD |
| Total Cash Per Share (mrq) | 0.29 AUD |
| Total Debt (mrq) | 0 AUD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 11.453 |
| Book Value Per Share (mrq) | 0.315 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -21107948 AUD |
| Levered Free Cash Flow (ttm) | -13186238 AUD |
Profile of Clarity Pharmaceuticals Ltd
| Country | Australia |
| State | NSW |
| City | Sydney |
| Address | National Innovation Centre |
| ZIP | 2015 |
| Phone | 61 2 9209 4037 |
| Website | https://www.claritypharmaceuticals.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Q&A For Clarity Pharmaceuticals Ltd Stock
What is a current CU6.AX stock price?
Clarity Pharmaceuticals Ltd CU6.AX stock price today per share is 2.64 AUD.
How to purchase Clarity Pharmaceuticals Ltd stock?
You can buy CU6.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Clarity Pharmaceuticals Ltd?
The stock symbol or ticker of Clarity Pharmaceuticals Ltd is CU6.AX.
Which industry does the Clarity Pharmaceuticals Ltd company belong to?
The Clarity Pharmaceuticals Ltd industry is Biotechnology.
How many shares does Clarity Pharmaceuticals Ltd have in circulation?
The max supply of Clarity Pharmaceuticals Ltd shares is 306.35M.
What is Clarity Pharmaceuticals Ltd Price to Earnings Ratio (PE Ratio)?
Clarity Pharmaceuticals Ltd PE Ratio is now.
What was Clarity Pharmaceuticals Ltd earnings per share over the trailing 12 months (TTM)?
Clarity Pharmaceuticals Ltd EPS is -0.12 AUD over the trailing 12 months.
Which sector does the Clarity Pharmaceuticals Ltd company belong to?
The Clarity Pharmaceuticals Ltd sector is Healthcare.